PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026
PAVmed (PAVM) will host its third-quarter 2026 business update conference call and webcast on November 13, 2026, at 8:30 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PAVmed (PAVM) will host its third-quarter 2026 business update conference call and webcast on November 13, 2026, at 8:30 AM ET.
Chairman and CEO Lishan Aklog will discuss operations and growth strategy. President and CFO Dennis McGrath will discuss third-quarter financial results. The webcast will be available through investor relations at pavmed.com, with a replay available for 30 days after the call.
Details
Market Reaction – LUCD
On Oct 30, the day this news came out, the latest delayed price for LUCD is 1.67% below the previous close. Our momentum scanner has recorded 7 alerts for this stock so far that day. The latest delayed price is $0.43. Relative volume is elevated at 2.8x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call and Webcast at 8:30 AM ET
The webcast will be available at the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone,
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.
About PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics (Nasdaq: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.
For more information about PAVmed, please visit pavmed.com.
For more information about Lucid Diagnostics, please visit luciddx.com.
For more information about Veris Health, please visit verishealth.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/pavmed-to-hold-third-quarter-2026-business-update-conference-call-and-webcast-on-november-13-2026-302924383.html
SOURCE PAVmed Inc.